

**GENAISSANCE  
PHARMACEUTICALS**

FIVE SCIENCE PARK  
NEW HAVEN, CT 06511  
TEL. 203.773.1450  
FAX. 203.562.9377  
WWW.GENAISSANCE.COM

To: Commissioner for Patents  
Date: February 23, 2005  
Company: U.S. Patent & Trademark Office  
Pages: 9 (including cover sheet)

Fax Number: 703.872.9306  
From: Matthew M. Catlett  
Subject: US Appl. No. 09/811,285

**RECEIVED**  
**CENTRAL FAX CENTER**

**FEB 23 2005**

Please see attached.

Best Available Copy

The document(s) accompanying this facsimile may contain information from Genaissance Pharmaceuticals that is confidential, proprietary, and/or legally privileged. The information is intended only for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or the taking of any action in reliance on the contents of this faxed information is strictly prohibited, and the document(s) should be returned to this company immediately. If you have received this fax in error, please notify us by telephone immediately, so that Genaissance may arrange for the return of the original document(s) at no cost to you.

RECEIVED  
CENTRAL FAX CENTER

NO. 209 P. 2

Docket No. MGYH-0363 US2

FEB 23 2005

Best Available Copy


## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Connie M. Drysdale *et al.*  
Application No.: 09/811,285  
Filed: March 16, 2001 (continuation of PCT/US00/10125, filed April 13, 2000)  
Confirmation No.: 2691  
Group No.: 1646  
Examiner: Murphy, J.F.  
For:  $\beta_2$ -ADRENERGIC RECEPTOR HAPLOTYPES (as amended herein)

Commissioner for Patents

Certificate of Facsimile Transmission

I hereby certify under 37 C.F.R. § 1.8 that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office, Commissioner for Patents, TC 1600, at (703) 872-9306, on Feb. 23, 2005.

  
Matthew M. CordertRESPONSE TO OFFICE ACTION UNDER 37 C.F.R. § 1.111

In response to the Office Action dated November 24, 2004 regarding the above-captioned application, please amend the application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Abstract** begin on page 3 of this paper.

**Amendments to the Claims** begin on page 4 of this paper.

**Remarks** begin on page 6 of this paper.